echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > As long as it is domestically produced, the results of the 21 million device purchase order will be announced (with a list attached)

    As long as it is domestically produced, the results of the 21 million device purchase order will be announced (with a list attached)

    • Last Update: 2022-03-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      21 million large purchase orders
     
      Recently, Ganzhou City Public Resource Trading Center released a project bidding information.
    The Quannan County
    Hospital of Integrated Traditional Chinese and Western Medicine in Jiangxi Province purchased a batch of medical equipment, including suspended DR, mammography, color Doppler ultrasound, monitor, defibrillator, anesthesia 82 kinds of medical equipment such as machines and nucleic acid extractors, with a total budget of 21,618,672 yuan, and it is clear that only domestic products are required
    .
     
      In the end, Sinopharm Holding Jiangxi Medical Device Supply Chain Co.
    , Ltd.
    won the bid for the project with 21,511,280 yuan.
    The winning product brands include GE, Mindray, Shenzhen Libang, Yuyue, Shanchao, Ningbo Dawei, Tianlong, Dongfeng Hongxing, Laoken, etc.
    business
    .
     
      
     
      Prioritize the purchase of domestic equipment
     
      It is worth noting that all the products that won the bid this time are "domestic products"
    .
     
      Among them, the winning price of a single GE Medical Suspension DR (Definium Tempo) is 2.
    587 million.
    This product is a new product of GE Medical's 2021 DR series, which also belongs to the "domestic" category

    .
     
      It is reported that the Definium Tempo series products are completely designed in China, designed for China, and made in China
    .
     
      The Senographe Crystal Nova, a digital mammography diagnostic system for GE Healthcare, is not only part of the image post-processing R&D team in Beijing, but GE also places the entire production line in its factory in Beijing
    .
     
     
      According to the provisions of China's "Government Procurement Law", government procurement is based on the principle of purchasing domestic goods, projects and services, and the "domestic goods" mentioned here also include foreign brand equipment produced by wholly foreign-owned joint ventures in China.

    .
     
     
     
      For a long time, China's medical device market has been dominated by foreign companies.
    With in-depth insights into the Chinese market, giant machinery companies such as Philips, Siemens, Medtronic, Johnson & Johnson, and Abbott have been accelerating the deployment of "localization" strategies in recent years

    .
     
      The layout of giant machinery enterprises is "localized"
     
      Today, multinational machinery companies are no longer limited to selling products as agents in China or building factories and manufacturing, but directly carry out innovation and research and development in China.
    Whether they are building innovation platforms or participating in cutting-edge technology projects, they are trying to give the local Chinese Innovation genes, so as to form an innovation ecology, so as to consolidate the company's own market position

    .
     
      In the past six months, in addition to the latest DR released by GE Healthcare, Siemens' first "domestic" ultrasonic diagnostic equipment has also been officially rolled out in Shanghai!
     
      Mr.
    Ma Jinxian, General Manager of the Ultrasound Division of Siemens Healthineers Greater China, once said: In response to the needs of Chinese customers, Siemens Healthineers actively promotes the local production of ultrasound equipment

    .
     
      Recently, according to the first financial information, Medtronic Group , the world's largest medical device
    company, is considering increasing the production scale of its core cardiovascular devices in China .
    It is reported that Medtronic will invest hundreds of millions of RMB in Shanghai Lingang to establish related product lines

    .
     
      According to information disclosed by Lingang, the initial investment of the Medtronic Lingang project is about 300 million yuan, which will be used for the research and development and industrialization of cardiovascular disease-related products
    .
    The plant of the project is expected to be delivered in June this year, and will be put into production within 5 years after delivery.
    It is expected to reach production in the third year after it is put into production.
    The annual output value is expected to be about 300 million yuan after production

    .
     
      Gu Yushao, senior vice president of Medtronic and president of Greater China, said in an interview with the first financial reporter: "China's medical market has a huge unmet need.
    In the future, China will not only become the world's largest medical device market, but also will certainly Become one of the important sources of innovation for medical devices in the world

    .
    Medtronic will promote the local R&D and production plan of high-end product lines in China

    .
      21 million large purchase orders
     
      Recently, Ganzhou City Public Resource Trading Center released a project bidding information.
    The Quannan County
    Hospital of Integrated Traditional Chinese and Western Medicine in Jiangxi Province purchased a batch of medical equipment, including suspended DR, mammography, color Doppler ultrasound, monitor, defibrillator, anesthesia 82 kinds of medical equipment such as machines and nucleic acid extractors, with a total budget of 21,618,672 yuan, and it is clear that only domestic products are required
    .
     
      In the end, Sinopharm Holding Jiangxi Medical Device Supply Chain Co.
    , Ltd.
    won the bid for the project with 21,511,280 yuan.
    The winning product brands include GE, Mindray, Shenzhen Libang, Yuyue, Shanchao, Ningbo Dawei, Tianlong, Dongfeng Hongxing, Laoken, etc.
    business
    .
     
      
     
      Prioritize the purchase of domestic equipment
     
      It is worth noting that all the products that won the bid this time are "domestic products"
    .
     
      Among them, the winning price of a single GE Medical Suspension DR (Definium Tempo) is 2.
    587 million.
    This product is a new product of GE Medical's 2021 DR series, which also belongs to the "domestic" category

    .
     
      It is reported that the Definium Tempo series products are completely designed in China, designed for China, and made in China
    .
     
      The Senographe Crystal Nova, a digital mammography diagnostic system for GE Healthcare, is not only part of the image post-processing R&D team in Beijing, but GE also places the entire production line in its factory in Beijing
    .
     
     
      According to the provisions of China's "Government Procurement Law", government procurement is based on the principle of purchasing domestic goods, projects and services, and the "domestic goods" mentioned here also include foreign brand equipment produced by wholly foreign-owned joint ventures in China.

    .
     
     
     
      For a long time, China's medical device market has been dominated by foreign companies.
    With in-depth insights into the Chinese market, giant machinery companies such as Philips, Siemens, Medtronic, Johnson & Johnson, and Abbott have been accelerating the deployment of "localization" strategies in recent years

    .
     
      The layout of giant machinery enterprises is "localized"
     
      Today, multinational machinery companies are no longer limited to selling products as agents in China or building factories and manufacturing, but directly carry out innovation and research and development in China.
    Whether they are building innovation platforms or participating in cutting-edge technology projects, they are trying to give the local Chinese Innovation genes, so as to form an innovation ecology, so as to consolidate the company's own market position

    .
     
      In the past six months, in addition to the latest DR released by GE Healthcare, Siemens' first "domestic" ultrasonic diagnostic equipment has also been officially rolled out in Shanghai!
     
      Mr.
    Ma Jinxian, General Manager of the Ultrasound Division of Siemens Healthineers Greater China, once said: In response to the needs of Chinese customers, Siemens Healthineers actively promotes the local production of ultrasound equipment

    .
     
      Recently, according to the first financial information, Medtronic Group , the world's largest medical device
    company, is considering increasing the production scale of its core cardiovascular devices in China .
    It is reported that Medtronic will invest hundreds of millions of RMB in Shanghai Lingang to establish related product lines

    .
     
      According to information disclosed by Lingang, the initial investment of the Medtronic Lingang project is about 300 million yuan, which will be used for the research and development and industrialization of cardiovascular disease-related products
    .
    The plant of the project is expected to be delivered in June this year, and will be put into production within 5 years after delivery.
    It is expected to reach production in the third year after it is put into production.
    The annual output value is expected to be about 300 million yuan after production

    .
     
      Gu Yushao, senior vice president of Medtronic and president of Greater China, said in an interview with the first financial reporter: "China's medical market has a huge unmet need.
    In the future, China will not only become the world's largest medical device market, but also will certainly Become one of the important sources of innovation for medical devices in the world

    .
    Medtronic will promote the local R&D and production plan of high-end product lines in China

    .
      21 million large purchase orders
      21 million large purchase orders
     
      Recently, Ganzhou City Public Resource Trading Center released a project bidding information.
    The Quannan County
    Hospital of Integrated Traditional Chinese and Western Medicine in Jiangxi Province purchased a batch of medical equipment, including suspended DR, mammography, color Doppler ultrasound, monitor, defibrillator, anesthesia 82 kinds of medical equipment such as machines and nucleic acid extractors, with a total budget of 21,618,672 yuan, and it is clear that only domestic products are required
    .
    Hospital Procurement Hospital Hospital Procurement _
     
      In the end, Sinopharm Holding Jiangxi Medical Device Supply Chain Co.
    , Ltd.
    won the bid for the project with 21,511,280 yuan.
    The winning product brands include GE, Mindray, Shenzhen Libang, Yuyue, Shanchao, Ningbo Dawei, Tianlong, Dongfeng Hongxing, Laoken, etc.
    business
    .
    enterprise enterprise enterprise
     
      
      
     
      Prioritize the purchase of domestic equipment
      Prioritize the purchase of domestic equipment
     
      It is worth noting that all the products that won the bid this time are "domestic products"
    .
     
      Among them, the winning price of a single GE Medical Suspension DR (Definium Tempo) is 2.
    587 million.
    This product is a new product of GE Medical's 2021 DR series, which also belongs to the "domestic" category

    .
     
      It is reported that the Definium Tempo series products are completely designed in China, designed for China, and made in China
    .
     
      The Senographe Crystal Nova, a digital mammography diagnostic system for GE Healthcare, is not only part of the image post-processing R&D team in Beijing, but GE also places the entire production line in its factory in Beijing
    .
     
     
      According to the provisions of China's "Government Procurement Law", government procurement is based on the principle of purchasing domestic goods, projects and services, and the "domestic goods" mentioned here also include foreign brand equipment produced by wholly foreign-owned joint ventures in China.

    .
     
     
     
     
      For a long time, China's medical device market has been dominated by foreign companies.
    With in-depth insights into the Chinese market, giant machinery companies such as Philips, Siemens, Medtronic, Johnson & Johnson, and Abbott have been accelerating the deployment of "localization" strategies in recent years

    .
     
      The layout of giant machinery enterprises is "localized"
      The layout of giant machinery enterprises is "localized"
     
      Today, multinational machinery companies are no longer limited to selling products as agents in China or building factories and manufacturing, but directly carry out innovation and research and development in China.
    Whether they are building innovation platforms or participating in cutting-edge technology projects, they are trying to give the local Chinese Innovation genes, so as to form an innovation ecology, so as to consolidate the company's own market position

    .
    agent agent agent
     
      In the past six months, in addition to the latest DR released by GE Healthcare, Siemens' first "domestic" ultrasonic diagnostic equipment has also been officially rolled out in Shanghai!
     
      Mr.
    Ma Jinxian, General Manager of the Ultrasound Division of Siemens Healthineers Greater China, once said: In response to the needs of Chinese customers, Siemens Healthineers actively promotes the local production of ultrasound equipment

    .
     
      Recently, according to the first financial information, Medtronic Group , the world's largest medical device
    company, is considering increasing the production scale of its core cardiovascular devices in China .
    It is reported that Medtronic will invest hundreds of millions of RMB in Shanghai Lingang to establish related product lines

    .
    medical device medical device medical device
     
      According to information disclosed by Lingang, the initial investment of the Medtronic Lingang project is about 300 million yuan, which will be used for the research and development and industrialization of cardiovascular disease-related products
    .
    The plant of the project is expected to be delivered in June this year, and will be put into production within 5 years after delivery.
    It is expected to reach production in the third year after it is put into production.
    The annual output value is expected to be about 300 million yuan after production

    .
     
      Gu Yushao, senior vice president of Medtronic and president of Greater China, said in an interview with the first financial reporter: "China's medical market has a huge unmet need.
    In the future, China will not only become the world's largest medical device market, but also will certainly Become one of the important sources of innovation for medical devices in the world

    .
    Medtronic will promote the local R&D and production plan of high-end product lines in China

    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.